Cellestetix Secures $2 Million Investment

Cellestetix, a Turkish biotechnology company focused on discovering, developing, and commercializing plant-based exosome formulations for regenerative beauty applications, has raised $2 million in funding.

The round was completed with the participation of Pragma Capital Partners (PCP), APY Ventures, Arya Ventures, Maxis Ventures, İstCapital, Ahmet Ramiz, and other angel investors.

The investment will be used to accelerate Cellestetix’s growth in the U.S. market and to support ongoing new product development efforts.

Cellestetix was founded by Dr. Polen Koçak and Dr. Merve Yıldırım, both of whom previously conducted research at Harvard Medical School and MD Anderson. The founders bring over a decade of experience in biotechnology, genetics, bioengineering, and gene therapy.

Initially launched as an R&D platform for cancer and wound care, the company later pivoted its focus following the addition of former Estée Lauder executives to its management team. Today, Cellestetix concentrates on cosmetic applications of plant-based exosomes under its U.S.-focused brand, SickScience.

Through its SickScience Labs brand, Cellestetix offers solutions for skin regeneration and beauty care using plant-based exosome formulations. The products, which entered the U.S. market in early 2024, have been featured in leading media outlets such as WWD, People Magazine, The Today Show, and Forbes.

Cellestetix aims to position itself as an independent brand in the U.S. under SickScience Labs, Inc. While exosome and product R&D activities are carried out in laboratories in Türkiye, final product manufacturing and marketing operations are conducted in the United States.